References Tumor M2-PK Antibodies
icon_pdfPlease click here to download the references as pdf-file

Immunostaining of lung tumors

  • Eigenbrodt, E., Reinacher M., Scheefers-Borchel, U., Scheefers, H., Friis, R.: Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit. Rev. Oncogenesis (1992), 3: 91-115.
  • Mazurek, S., Scheefers-Borchel, U., Scheefers, H., Michel, A., Basenau, D., Fischer, G., Dahlmann, N., Laumen, R. and Eigenbrodt, E.: Die Bedeutung der Pyruvatkinase in der Onkologie. Notabene medici (1993), 3: 97-104.
    Hugo, F., Fischer, G. and Eigenbrodt, E.: Quantitative detection of Tumor M2-PK in serum and plasma. Anticancer Res. (1999), 19: 2753-2758.
  • Schneider J., Morr H., Velcovsky H.-G., Weisse, G. and Eigenbrodt, E.: Quantitative detection of Tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases. Cancer Detect. Prev. (2000), 24: 531-535.
  • Schneider, J.; Neu, K.; Grimm, H.; Velcovsky, H.-G.; Weisse, G. and Eigenbrodt, E.: Tumor M2-Pyruvate Kinase in Lung Cancer Patients: Immunohistochemical Detection and Disease Monitoring. Anticancer Research (2002), 22: 311-318.

Immunostaining of renal carcinomas

  • Brinck, U., Eigenbrodt, E., Oehmke, M., Mazurek, S. Fischer, G.: L- and M2- Pyruvate Kinase Expression in Renal Cell Carcinomas and their Metastases. Virchows Arch. (1994), 424: 177-185.
  • Wechsel, H.W., Petri, E., Bichler, K-H. and Feil, G.: Marker for Renal Cell Carcinoma (RCC): The Dimeric Form of Pyruvate Kinase Type M2 (Tumor M2-PK). Anticancer Research (1999), 19: 2583-2590.

Immunostaining of colorectal tumors

  • Mazurek, S., Scheefers-Borchel, U., Scheefers, H., Michel, A., Basenau, D., Fischer, G., Dahlmann, N., Laumen, R. and Eigenbrodt, E.: Die Bedeutung der Pyruvatkinase in der Onkologie. Notabene medici (1993), 3: 97-104.
  • Eigenbrodt, E., Basenau, D., Holthusen, S., Mazurek, S. and Fischer, G.: Quantification of Tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. Anticancer Res. (1997), 17: 3153-3156.
  • Hardt, P.D., Mazurek, S., Klör, H.-U. and Eigenbrodt, E.: Neuer Test zum Nachweis von Darmkrebs. Von der Grundlagenforschung zur klinischen Anwendung: Kebszellennachweis anhand von Tumor M2-PK™. Spiegel der Forschung(2004), 21. Jg./Nr. ½: 15-19.

Immunostaining of oesophagus carcinomas

  • Koss, K., Harrison, R.F., Gregory, J., Darnton, S.J., Anderson, M.R. and Jankowski, J.A.Z.: The metabolic marker tumour pyruvate kinase type M2 (tumor M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barett′s oesophagus. J. Clin. Pathol. (2004) 57: 1156-1159.

Immunostaining of liver tissues

  • Steinberg, P., Weisse, G., Eigenbrodt, E. and Oesch, F.: Expression of L- and M2-pyruvate kinase in proliferating oval cells and cholangicellular lesions developing in the livers of rats fed a methyl-deficient diet. Carcinogenesis (1994), 15: 125-127.
  • Steinberg, P., Klingelhöffer, A., Schäfer, A., Wüst, G., Weiße, G., Oesch, F. and Eigenbrodt, E.: Expression of pyruvate kinase type M2 in preneoplastic hepatic foci of N-nitrosomorpholine-treated rats. Virchows Arch. (1999), 434: 213-220.
  • M2-PK Western blots, immunoprecipitations and immunofluorescent analysis
    Zwerschke, W., Mazurek, S., Massimi, P., Banks, L., Eigenbrodt, E., Jansen-Dürr, P.: Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc. Natl. Acad. Sci. USA (1999), 96: 1291-1296.
  • Mazurek, S., Weisse, G., Wüst, G., Schäfer-Schwebel, A., Eigenbrodt, E. and Friis, R.: Energy metabolism in the involuting mammary gland. In vivo (1999), 13: 467-478.
  • Garcia-Gonzalo, F.R., Cruz, C., Munoz,. P., Mazurek, S., Eigenbrodt, E., Ventura, F., Bartrons, R., Rosa, J.L.: Interaction between HERC1 and M2-type pyruvate kinase. FEBS Lett. (2003), 539: 78-84.
  • Mazurek, S., Zwerschke, W., Jansen-Dürr, P., and Eigenbrodt, E.: Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic enzyme complex. Biochem. J. (2001), 356: 247-256.
    Yoo, B.C., Ku, J.L., Hong, S.H., Shin, Y.K., Park, S.Y., Kim, H.K., and Park, J.G.: Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines. Int. J. Cancer (2004) 108 : 532-539.
  • Mazurek, S., Drexler, H.C., Troppmair, J., Eigenbrodt, E., and Rapp, U.R.: Regulation of pyruvate kinase type M2 by A-Raf: a possible glycolytic stop or go mechanism. Anticancer Res. (2007), 27: 3963-3971.

Metabolic background of M2-PK

  • Mazurek, S., Boschek, C.B., Hugo, F., and Eigenbrodt, E.: Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol. (2005) 15: 300-308.